Agostino Virdis

List of Publications by Year in Descending Order

126 papers	7,961 citations	46 h-index	88 g-index
141 ext. papers	8,967 ext. citations	5.7 avg, IF	5.71 L-index

#	Paper	IF	Citations
126	Arterial Hypertension and Cardiopulmonary Function: The Value of a Combined Cardiopulmonary and Echocardiography Stress Test.. *High Blood Pressure and Cardiovascular Prevention*, **2022**, 29, 145	2.9	
125	New Noninvasive Methods to Evaluate Microvascular Structure and Function.. *Hypertension*, **2022**, HYPERTENSIONAHA12	8.3	2
124	Fasting small vessels to prevent microvascular ageing? The experience of a microvascular research group working in the shadow of the leaning tower.. *European Heart Journal*, **2022**, 43, 442-444	9.5	
123	The relationship between telomere length and putative markers of vascular ageing: A systematic review and meta-analysis. *Mechanisms of Ageing and Development*, **2021**, 201, 111604	5.6	1
122	Microvascular ageing links metabolic disease to age-related disorders: the role of oxidative stress and inflammation in promoting microvascular dysfunction. *Journal of Cardiovascular Pharmacology*, **2021**, 78,	3.1	4
121	Microvascular Inflammation and Cardiovascular Prevention: The Role of Microcirculation as Earlier Determinant of Cardiovascular Risk. *High Blood Pressure and Cardiovascular Prevention*, **2021**, 1	2.9	1
120	Donepezil improves vascular function in a mouse model of Alzheimer's disease. *Pharmacology Research and Perspectives*, **2021**, 9, e00871	3.1	1
119	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. *Journal of Hypertension*, **2021**, 39, 62-69	1.9	17
118	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. *Journal of Hypertension*, **2021**, 39, 333-340	1.9	17
117	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. *European Heart Journal*, **2021**, 42, 2590-2604	9.5	24
116	The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. *Scientific Reports*, **2021**, 11, 6515	4.9	7
115	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. *Journal of Nephrology*, **2021**, 1	4.8	15
114	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. *Journal of Healthcare Engineering*, **2021**, 2021, 5556207	3.7	2
113	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. *Science Advances*, **2021**, 7,	14.3	97
112	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. *European Journal of Preventive Cardiology*, **2021**,	3.9	2
111	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. *Clinical Research in Cardiology*, **2021**, 110, 1073-1082	6.1	8
110	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. *Journal of Human Hypertension*, **2021**,	2.6	3

109	Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. *European Journal of Heart Failure*, **2021**, 23, 1858-1871	12.3	23
108	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. *Frontiers in Cardiovascular Medicine* , **2021**, 8, 713652	5.4	1
107	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. *Cardiovascular Research*, **2020**, 116, 429-437	9.9	13
106	Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. *Obesity Research and Clinical Practice*, **2020**, 14, 205-209	5.4	56
105	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
104	Letter to the Editor: Importance of metabolic health in the era of COVID-19. *Metabolism: Clinical and Experimental*, **2020**, 108, 154247	12.7	19
103	Microvascular Endothelial Dysfunction in Hypertension. *Updates in Hypertension and Cardiovascular Protection*, **2020**, 95-101	0.1	
102	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. *Hypertension*, **2020**, 75, 302-308	8.5	76
101	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. *Journal of Hypertension*, **2020**, 38, 412-419	1.9	34
100	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. *Open Forum Infectious Diseases*, **2020**, 7, ofaa563	1	32
99	Obesity-Related Endothelial Dysfunction: moving from classical to emerging mechanisms. *Endocrine and Metabolic Science*, **2020**, 1, 100063	1	1
98	Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. *Diabetes Care*, **2020**, 43, 2345-2348	14.6	77
97	Angiotensin II and vascular damage in hypertension: Role of oxidative stress and sympathetic activation. *Vascular Pharmacology*, **2019**, 115, 13-17	5.9	46
96	Microvascular Endothelial Dysfunction in Patients with Obesity. *Current Hypertension Reports*, **2019**, 21, 32	4.7	27
95	Investing in your arteries by spending more time in education. *European Journal of Preventive Cardiology*, **2019**, 26, 1092-1095	3.9	0
94	Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms. *High Blood Pressure and Cardiovascular Prevention*, **2019**, 26, 321-329	2.9	13
93	Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2587-2598	6.7	45
92	The Role of Arterial Hypertension in Mitral Valve Regurgitation. *Current Hypertension Reports*, **2019** , 21, 20	4.7	0

91	Drug-induced hypertension: Know the problem to know how to deal with it. *Vascular Pharmacology*, **2019**, 115, 84-88	5.9	6
90	Arterial hypertension in patients under antineoplastic therapy: a systematic review. *Journal of Hypertension*, **2019**, 37, 884-901	1.9	16
89	Microvascular Endothelial Dysfunction in Human Obesity: Role of TNF-*Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 341-348	5.6	25
88	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. *European Heart Journal*, **2019**, 40, 383-391	9.5	33
87	Age- and Sex-Specific Reference Values for Media/Lumen Ratio in Small Arteries and Relationship With Risk Factors. *Hypertension*, **2018**, 71, 1193-1200	8.5	14
86	Endothelial Function. *Updates in Hypertension and Cardiovascular Protection*, **2018**, 127-134	0.1	1
85	Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. *High Blood Pressure and Cardiovascular Prevention*, **2018**, 25, 197-202	2.9	21
84	Essential Hypertension and Functional Microvascular Ageing. *High Blood Pressure and Cardiovascular Prevention*, **2018**, 25, 35-40	2.9	14
83	Albuminuria and diabetes: a question of eye and skin points of view. *Journal of Hypertension*, **2018**, 36, 1036-1037	1.9	1
82	Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: A randomised controlled clinical trial. *International Journal of Cardiology* , **2018**, 271, 263-268	3.2	25
81	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. *PLoS ONE*, **2018**, 13, e0195502	3.7	33
80	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO4-2-47	0	
79	Aging Modulates the Influence of Arginase on Endothelial Dysfunction in Obesity. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 2474-2483	9.4	29
78	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. *Frontiers in Pharmacology*, **2018**, 9, 1094	5.6	33
77	Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome. *Vascular Pharmacology*, **2017**, 92, 16-21	5.9	9
76	Different Impact of Essential Hypertension on Structural and Functional Age-Related Vascular Changes. *Hypertension*, **2017**, 69, 71-78	8.5	48
75	Environmental Factors and Hypertension. *Current Pharmaceutical Design*, **2017**, 23, 3239-3246	3.3	15
74	Gender differences in the relationships between psychosocial factors and hypertension. *Maturitas*, **2016**, 93, 58-64	5	11

73	Endothelial Dysfunction in Obesity: Role of Inflammation. *High Blood Pressure and Cardiovascular Prevention*, **2016**, 23, 83-5	2.9	44
72	Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin. *Journal of Pediatric and Adolescent Gynecology*, **2016**, 29, 489-495	2	10
71	Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. *Vascular Pharmacology*, **2016**, 76, 62-71	5.9	22
70	Human Ghrelin: A Gastric Hormone with Cardiovascular Properties. *Current Pharmaceutical Design*, **2016**, 22, 52-8	3.3	26
69	Endothelial Dysfunction in Resistance Arteries of Hypertensive Humans: Old and New Conspirators. *Journal of Cardiovascular Pharmacology*, **2016**, 67, 451-7	3.1	21
68	Impact of apocynin on vascular disease in hypertension. *Vascular Pharmacology*, **2016**, 87, 1-5	5.9	23
67	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. *Journal of Clinical Hypertension*, **2016**, 18, 551-6	2.3	36
66	Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of NAD(P)H oxidase. *European Heart Journal*, **2015**, 36, 3023-30	9.5	25
65	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. *Arthritis Research and Therapy*, **2015**, 17, 277	5.7	46
64	Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. *European Heart Journal*, **2015**, 36, 784-94	9.5	95
63	Use of Fixed Combination Therapies to Improve Blood Pressure Control in the Clinical Management of Hypertension: A Key Opportunity. *High Blood Pressure and Cardiovascular Prevention*, **2015**, 22, 427-8	2.9	
62	Clinical management of drug-induced hypertension: 2013 Practical Recommendations of the Italian Society of Hypertension (SIIA). *High Blood Pressure and Cardiovascular Prevention*, **2014**, 21, 77-9	2.9	7
61	Obesità e infiammazione: il ruolo della disfunzione endoteliale. *L Endocrinologo*, **2014**, 15, 130-134	0	
60	Evaluation of microvascular structure in humans: a 'state-of-the-art' document of the Working Group on Macrovascular and Microvascular Alterations of the Italian Society of Arterial Hypertension. *Journal of Hypertension*, **2014**, 32, 2120-9; discussion 2129	1.9	40
59	Impact of inflammation on vascular disease in hypertension. *Maturitas*, **2014**, 78, 179-83	5	72
58	Response to Endothelial nitric oxide synthase, cyclooxygenase-2, and essential hypertension: is there an interaction?. *Hypertension*, **2013**, 62, e16	8.5	1
57	The eye and the heart. *European Heart Journal*, **2013**, 34, 1270-8	9.5	211
56	Poor sleep quality and resistant hypertension. *Sleep Medicine*, **2013**, 14, 1157-63	4.6	71

55	Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. *British Journal of Pharmacology*, **2013**, 169, 554-66	8.6	14
54	Hypertension and cardiometabolic risk factors. *International Journal of Hypertension*, **2013**, 2013, 634798	2.4	2
53	Characterisation of hypertensive patients with improved endothelial function after dark chocolate consumption. *International Journal of Hypertension*, **2013**, 2013, 985087	2.4	10
52	Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. *Hypertension*, **2013**, 62, 337-44	8.5	84
51	Vascular dysfunction in a mouse model of Rett syndrome and effects of curcumin treatment. *PLoS ONE*, **2013**, 8, e64863	3.7	29
50	Microvascular endothelial dysfunction in obesity and hypertension. *Current Pharmaceutical Design*, **2013**, 19, 2382-9	3.3	51
49	Hypertension and endothelial dysfunction: therapeutic approach. *Current Vascular Pharmacology*, **2012**, 10, 42-60	3.3	105
48	Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. *European Heart Journal*, **2012**, 33, 1530-8	9.5	48
47	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. *European Heart Journal*, **2012**, 33, 2225-34	9.5	26
46	Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. *Journal of the American College of Cardiology*, **2011**, 58, 238-47	15.1	83
45	Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II. *International Journal of Hypertension*, **2011**, 2011, 916310	2.4	66
44	Effects of antihypertensive treatment on endothelial function. *Current Hypertension Reports*, **2011**, 13, 276-81	4.7	45
43	How to evaluate microvascular organ damage in hypertension: assessment of endothelial function. *High Blood Pressure and Cardiovascular Prevention*, **2011**, 18, 163-7	2.9	16
42	The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 920-7	5.6	21
41	Human endothelial dysfunction: EDCFs. *Pflugers Archiv European Journal of Physiology*, **2010**, 459, 1015-23	4.6	60
40	Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. *Hypertension*, **2009**, 53, 1008-16	8.5	56
39	Inducible nitric oxide synthase is involved in endothelial dysfunction of mesenteric small arteries from hypothyroid rats. *Endocrinology*, **2009**, 150, 1033-42	4.8	32
38	Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. *Current Hypertension Reports*, **2009**, 11, 190-6	4.7	49

37	Vascular reactivity in patients with undifferentiated connective tissue diseases. *Atherosclerosis*, **2009**, 203, 185-91	3.1	10
36	Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. *Hypertension*, **2007**, 49, 679-86	8.5	63
35	Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 5076-82	5.6	124
34	Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. *Journal of the American College of Cardiology*, **2006**, 48, 508-15	15.1	98
33	Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. *Journal of Pharmacology and Experimental Therapeutics*, **2005**, 312, 945-53	4.7	79
32	Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. *Circulation*, **2004**, 110, 2233-40	16.7	270
31	Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. *Hypertension*, **2004**, 43, 399-404	8.5	97
30	Endothelial Dysfunction, Vascular Damage and Clinical Events. *High Blood Pressure and Cardiovascular Prevention*, **2004**, 11, 15-27	2.9	1
29	Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. *Journal of Hypertension*, **2004**, 22, 535-42	1.9	180
28	Small artery mechanics in hyperhomocysteinemic mice: effects of angiotensin II. *Journal of Hypertension*, **2004**, 22, 959-66	1.9	39
27	Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. *Hypertension*, **2003**, 41, 950-5	8.5	41
26	Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. *Journal of Hypertension*, **2003**, 21, 189-98	1.9	37
25	Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. *Journal of Hypertension*, **2003**, 21, 2275-80	1.9	26
24	Vascular inflammation: a role in vascular disease in hypertension?. *Current Opinion in Nephrology and Hypertension*, **2003**, 12, 181-7	3.5	139
23	Is Endothelial Dysfunction a Measurable Endpoint in Hypertension?. *High Blood Pressure and Cardiovascular Prevention*, **2003**, 10, 19-25	2.9	
22	Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 3731-7	5.6	317
21	Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1352-7	9.4	69
20	Spironolactone improves angiotensin-induced vascular changes and oxidative stress. *Hypertension*, **2002**, 40, 504-10	8.5	347

19	Endothelial function in hypertension: role of gender. *Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension*, **2002**, 20, S11-6		3
18	Role of endothelin in the control of peripheral vascular tone in human hypertension. *Heart Failure Reviews*, **2001**, 6, 277-85	5	32
17	Age-related reduction of NO availability and oxidative stress in humans. *Hypertension*, **2001**, 38, 274-9	8.5	523
16	Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. *Hypertension*, **2001**, 37, 943-8	8.5	134
15	Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. *Journal of the American College of Cardiology*, **2001**, 38, 1106-15	15.1	82
14	Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. *Current Hypertension Reports*, **2000**, 2, 64-70	4.7	57
13	Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. *Hypertension*, **2000**, 35, 501-6	8.5	163
12	Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. *Circulation*, **2000**, 101, 2896-901	16.7	352
11	Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. *Circulation*, **1999** , 100, 1400-5	16.7	113
10	Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. *Circulation*, **1999**, 100, 1680-3	16.7	108
9	Adenosine causes the release of active renin and angiotensin II in the coronary circulation of patients with essential hypertension. *Journal of the American College of Cardiology*, **1999**, 33, 1677-84	15.1	4
8	Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation*, **1998**, 97, 2222-9	16.7	625
7	Endothelial function and common carotid artery wall thickening in patients with essential hypertension. *Hypertension*, **1998**, 32, 25-32	8.5	117
6	Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. *Journal of Hypertension*, **1998**, 16, 447-56	1.9	77
5	Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. *Hypertension*, **1997**, 29, 274-9	8.5	183
4	Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. *Circulation*, **1997**, 96, 849-55	16.7	48
3	Hypertension causes premature aging of endothelial function in humans. *Hypertension*, **1997**, 29, 736-43	8.5	232
2	Aging and endothelial function in normotensive subjects and patients with essential hypertension. *Circulation*, **1995**, 91, 1981-7	16.7	492

1	Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. *Circulation*, **1995**, 92, 2911-8	16.7	109